Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CYP1B1	1545	2-METHOXYESTRADIOL	CHEMBL299613		DrugBank	12810639
CYP1B1	1545	LETROZOLE	CHEMBL1444		NCI	18256205
CYP1B1	1545	MEDROXYPROGESTERONE ACETATE	CHEMBL717		NCI	10764452
CYP1B1	1545	AMINOGLUTETHIMIDE	CHEMBL488		NCI	18256205
CYP1B1	1545	EXEMESTANE	CHEMBL1200374		NCI	18256205
CYP1B1	1545	FADROZOLE	CHEMBL9298		NCI	18256205
CYP1B1	1545	PACLITAXEL	CHEMBL428647		PharmGKB
CYP1B1	1545	FORMESTANE	CHEMBL132530		NCI	18256205
CYP1B1	1545	CHRYSIN	CHEMBL117	inhibitor	GuideToPharmacologyInteractions
CYP1B1	1545	ANASTROZOLE	CHEMBL1399		NCI	18256205
CYP1B1	1545	TOREMIFENE	CHEMBL1655		NCI	8262671
CYP1B1	1545	RIFAMPICIN	CHEMBL374478		NCI	6854335
CYP1B1	1545	ISOPROPYL ALCOHOL	CHEMBL582		NCI	6409434
CYP1B1	1545	SPIRONOLACTONE	CHEMBL1393		NCI	7079590

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CYP1B1	rs1056836	CC + CG	paclitaxel	efficacy	no	Response = complete clinical response (cCR). Some patients who had HER2 overexpressing tumors received trastuzumab at the same time as the paclitaxel. Also reported in article as CYP1B1*3;C>G. Gene is on negative strand, so annotated as *3 = C.	Genotypes CC + CG are not associated with increased response to paclitaxel in women with Breast Neoplasms as compared to genotype GG.	22527101	827922834
CYP1B1	rs1056836	C	gemcitabine	"efficacy","toxicity"	no	SNPs were selected based on prior literature and no alleles demonstrated any association with neurotoxicity or overall survival.	Allele C is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele G.	24361227	1184086220
CYP1B1	rs1056836	CC	cyclophosphamide	efficacy	yes	Patients with the CC genotype had a significantly lower pathological complete response rate as compared to those with the CG and GG genotypes.	Genotype CC is associated with decreased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CG + GG.	24958282	1444934576
CYP1B1	rs1056836	GG	docetaxel	efficacy	no	Patients with complete and partial pathological response to neo-adjuvant taxanes were considered as responders while patients with static and progressive disease with neo-adjuvant taxanes were considered as non-responders. (Complemented to represent on positive chromosomal strand)	Genotype GG is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to genotypes CC + CG.	24704000	1447954614
CYP1B1	rs10012	CC + CG	exemestane	metabolism/PK	no	No significant difference in exemestane concentrations were seen between the three genotypes. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CG are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype GG.	27549341	1448496262
CYP1B1	rs1056827	AA + AC	exemestane	metabolism/PK	no	No significant difference in exemestane concentrations were seen between the three genotypes. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes AA + AC are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype CC.	27549341	1448496718
CYP1B1	rs162555	CT + TT	exemestane	metabolism/PK	no	No significant difference in exemestane concentrations were seen between the three genotypes. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype CC.	27549341	1448497497
CYP1B1	rs10012	C	risperidone	efficacy	no	The C allele was initially significantly more frequent in patients designated as non-responders to risperidone (i.e. <50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	28696411	1450928104
CYP1B1	rs162561	GG	docetaxel	efficacy	no	Because of the skewed distribution of the rs162561 data genotypes the dominant model was selected (ß = 1.02; 95% CI: = 0.49–1.55; P = 1.77 × 10 - 4) and this association shows a trend toward significance after correction for multiple testing (PBonf = 0.079).	Genotype GG is associated with decreased response to docetaxel in people with Breast Neoplasms as compared to genotypes GT + TT.	30334909	1450342113
CYP1B1	rs1056827	A	risperidone	efficacy	no	The A allele was initially significantly more frequent in patients designated as non-responders to risperidone (i.e. <50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	28696411	1450928098